Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 8, 2026 | Immune Boost Capital Appoints Dr. Sai Nandi to Head Impact Investment Fund Targeting Immune-Mediated Diseases | Veteran biotech investor to steer IBC’s impact fund targeting early-stage therapies, diagnostics, and technologies for immune disorders. I look forward to building a platform that identifies breakthrough opportunities early and advances the... |
| Oct 21, 2025 | Arthritis National Research Foundation Appoints Schalon Newton, DBA, as Principal of Immune Boost Capital | Industry Veteran to Lead New Philanthropic Venture Fund Addressing Critical Early-Stage Funding Gap in Autoimmune Therapeutics and Diagnostics By combining ANRF’s philanthropic legacy with a disciplined investment model, we aim to create a ... |
Reviews 0
FAQ about Immune Boost Capital (IBC)
What has the press written about Immune Boost Capital (IBC)?
Parsers VC has collected 3 articles mentioning Immune Boost Capital (IBC), among them “Immune Boost Capital Appoints Dr. Sai Nandi to Head Impact Investment Fund Targeting Immune-Mediated Diseases” (Apr 8, 2026) and “Arthritis National Research Foundation Appoints Schalon Newton, DBA, as Principal of Immune Boost Capital” (Oct 21, 2025).
Is Immune Boost Capital (IBC) still active?
Yes, Immune Boost Capital (IBC) is active; its latest activity on Parsers VC dates from Oct 20, 2026.